Amylin Pharmaceuticals Inc. announced Tuesday that it hasfiled with the Securities and Exchange Commission (SEC) for asecondary offering of 2.5 million shares of common stock, withan overallotment option of 375,000 shares.
The San Diego companyLs stock (NASDAQ:AMLN) closedTuesday at $12.75, down $1.50 per share.
Underwriters for the offering are Morgan Stanley & Co. Inc. andAlex. Brown & Sons Inc. The company completed an initialpublic offering (IPO) last January, raising $64.4 million from asale of 4.6 million shares at $14 a share. After the currentoffering is completed, Amylin will have 19.8 million sharesoutstanding.
Proceeds from the offering will be used to conduct researchand development, including clinical trials, and for generalcorporate purposes.
(c) 1997 American Health Consultants. All rights reserved.